Connection

Co-Authors

This is a "connection" page, showing publications co-authored by PRAJNAN DAS and ROBERT A WOLFF.
Connection Strength

1.956
  1. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol. 2017 Dec; 40(6):555-560.
    View in: PubMed
    Score: 0.153
  2. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014 Nov 30; 5(22):11133-42.
    View in: PubMed
    Score: 0.124
  3. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 01; 29(22):3037-43.
    View in: PubMed
    Score: 0.098
  4. Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol. 2009 Nov 18; 4:55.
    View in: PubMed
    Score: 0.088
  5. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1175-80.
    View in: PubMed
    Score: 0.077
  6. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007 May 01; 109(9):1750-5.
    View in: PubMed
    Score: 0.074
  7. Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol. 2006 Oct 24; 1:41.
    View in: PubMed
    Score: 0.071
  8. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1378-83.
    View in: PubMed
    Score: 0.071
  9. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006 Jun; 29(3):219-24.
    View in: PubMed
    Score: 0.069
  10. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol. 2024 Nov 10; 42(32):3795-3805.
    View in: PubMed
    Score: 0.061
  11. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
    View in: PubMed
    Score: 0.060
  12. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 12; 24(12):1387-1398.
    View in: PubMed
    Score: 0.058
  13. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.053
  14. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2022 09 01; 114(1):163-172.
    View in: PubMed
    Score: 0.052
  15. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022 Mar; 33:66-69.
    View in: PubMed
    Score: 0.051
  16. CEA as a blood-based biomarker in anal cancer. Oncotarget. 2021 May 25; 12(11):1037-1045.
    View in: PubMed
    Score: 0.049
  17. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.043
  18. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. Clin Colorectal Cancer. 2019 12; 18(4):301-306.
    View in: PubMed
    Score: 0.043
  19. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2018 12 01; 24(23):5883-5894.
    View in: PubMed
    Score: 0.040
  20. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.039
  21. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.038
  22. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Jun; 40(3):277-282.
    View in: PubMed
    Score: 0.037
  23. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):403-415.
    View in: PubMed
    Score: 0.036
  24. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039.
    View in: PubMed
    Score: 0.036
  25. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):323-332.
    View in: PubMed
    Score: 0.036
  26. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174.
    View in: PubMed
    Score: 0.035
  27. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985.
    View in: PubMed
    Score: 0.035
  28. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910.
    View in: PubMed
    Score: 0.035
  29. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9.
    View in: PubMed
    Score: 0.035
  30. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):755-65.
    View in: PubMed
    Score: 0.033
  31. Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2015 Nov; 20(11):1247-52.
    View in: PubMed
    Score: 0.033
  32. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015 Jul; 54(7):971-8.
    View in: PubMed
    Score: 0.031
  33. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013 Nov 01; 119(21):3769-75.
    View in: PubMed
    Score: 0.028
  34. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30.
    View in: PubMed
    Score: 0.021
  35. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3487-95.
    View in: PubMed
    Score: 0.020
  36. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):735-43.
    View in: PubMed
    Score: 0.019
  37. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007 Jul 01; 110(1):47-55.
    View in: PubMed
    Score: 0.019
  38. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res. 2007 Mar; 1(2):44-8.
    View in: PubMed
    Score: 0.018
  39. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006 Dec 01; 107(11):2589-96.
    View in: PubMed
    Score: 0.018
  40. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):762-71.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.